{"id":76168,"date":"2026-05-06T14:41:10","date_gmt":"2026-05-06T14:41:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/76168\/"},"modified":"2026-05-06T14:41:10","modified_gmt":"2026-05-06T14:41:10","slug":"novo-bayer-ramaswamy-cellcentric-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/76168\/","title":{"rendered":"Novo, Bayer, Ramaswamy, CellCentric: Readout Newsletter"},"content":{"rendered":"

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n

Good morning. We\u2019ve got more earnings today, and my colleague Drew Joseph brings us a dispatch from Rome.<\/p>\n

The need-to-know this morning<\/p>\n

German drug maker Bayer said it is acquiring<\/a> Perfusion Therapeutics, a privately held developer of treatments for eye diseases.\u00a0<\/p>\n

Vivek Ramaswamy, the biotech executive-turned politician, won the Republican primary for governor of Ohio on Tuesday.\u00a0<\/p>\n

Madrigal Pharma said sales of its MASH drug Rezdiffra<\/a> were $311 million in the first quarter, topping Wall Street estimates.\u00a0<\/p>\n

United Therapeutics also reported earnings<\/a>.\u00a0<\/p>\n

Novo Nordisk saw its shares rise after being able to report some less-bad news.<\/p>\n

The Danish firm, which had been trailing rival Eli Lilly in the obesity drug market, has gained some recent momentum with the hugely successful launch of its Wegovy pill<\/a> in the U.S. And in releasing first quarter results Wednesday, Novo ticked up its guidance for the year, saying that adjusted sales will drop from 4% to 12% (the company previously said they would be down 5% to 13%), an identical shift also seen in its forecast for adjusted operating profit. The improving outlook is largely driven by better sales performance, Novo said.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter…\n","protected":false},"author":2,"featured_media":24825,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2759,4240,5794,272,5356],"class_list":{"0":"post-76168","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-biotechnology","9":"tag-drug-development","10":"tag-drug-prices","11":"tag-novo-nordisk","12":"tag-research"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116528158371748792","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=76168"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76168\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/24825"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=76168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=76168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=76168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}